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Simultaneous pancreas-kidney transplantation reduces excess and diabetic ESRD patients manifest the highest mortal-
mortality in type 1 diabetic patients with end-stage renal disease. ity rates of any group of ESRD patients. While renal
Background. Diabetic renal disease continues to be the most transplantation may improve diabetic ESRD patient sur-significant cause of end-stage renal disease (ESRD) in the United
vival, the diabetic state remains associated with poorStates. Renal transplantation improves diabetic ESRD patient
patient and graft outcomes. United Network for Organsurvival; however, the diabetic state remains associated with
poor patient survival. Simultaneous pancreas-kidney (SPK) Sharing (UNOS) data support this conclusion. Nondia-
transplantation can restore normoglycemia and thus may im- betic patients who receive a cadaveric renal transplant
prove outcomes. have a greater than 80% five-year survival, and a nearlyMethods. We assessed the impact of SPK on age-range–
90% five-year survival is documented for recipients ofmatched type 1 diabetic patients who underwent renal trans-
living-donor transplants [1]. However, patients with typeplantation at a single center. The observed/expected life span
and annual mortality rates (AMRs) were used as measures 1 diabetes who receive a cadaveric renal allograft have
of survival. A Cox proportional hazards analysis was used to a 73.4% five-year survival rate, and those receiving a
analyze the impact of potential variables on mortality in SPK living-donor renal allograft have an 84% five-year sur-recipients.
vival rate. To enhance these results, physicians and sur-Results. SPK transplantation (N 5 335) increased the ob-
geons have focused on improving immunosuppression,served/expected life span compared with diabetic cadaveric
(DM-Cad, N 5 147) and live-donor (DM-Live, N 5 160) trans- pretransplant medical evaluation, prophylactic medical
plant recipients (P 5 0.004) and significantly reduced the strategies, and simultaneously, honing the techniques of
AMRs (SPK, 1.5%; DM-Cad, 6.27%; DM-Live, 3.65%, P 5 simultaneous pancreas-kidney (SPK) transplantation.0.008, SPK vs. other DM). Moreover, the SPK observed/ex-
Simultaneous pancreas-kidney transplantation improvespected life span and AMR were not significantly different from
certain sequelae of diabetes, including retinopathy [2]that of age-range–matched nondiabetic transplant recipients
(N 5 492). The only variable that was significantly associated and neuropathy [3]. This occurs concomitant with the
with patient survival was discharge serum creatinine (relative demonstrable effects of SPK transplantation, restoration
risk 1.16, P # 0.0154). of renal function, and normoglycemia. Early studies em-Conclusion. These data demonstrate that SPK improves the
phasized concerns regarding the morbidity and mortalityability for type 1 diabetic patients to live more of their expected
associated with SPK transplantation [4–6]. They alsolife span. This suggests that glycemic control, even as a late
intervention in a diabetic patient’s lifetime, may beneficially raised a critical point: If SPK transplantation is to be
affect survival. effective as therapy for type 1 diabetes, then it must
improve the ability for patients to approximate a normal
life expectancy more than kidney transplantation alone.
Diabetic renal disease is the most significant cause of As such, a simple measure of the effectiveness of SPK
end-stage renal disease (ESRD) in the United States, transplantation is to evaluate the SPK recipient survival
as a ratio of the length of patient survival following the
Key words: transplantation, diabetes, survival, glycemic control, ESRD. transplant event compared with the average life span of
an age-matched healthy individual from the same popu-Received for publication August 26, 1999
lation [7].and in revised form November 9, 1999
Accepted for publication December 6, 1999 We used this outcome measure (observed/expected
life span) to address this question: How effective is SPKÓ 2000 by the International Society of Nephrology
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transplantation at our center in restoring normal life tested using the log-rank test. For additional analyses,
the annual mortality rate (AMR) was also calculated.expectancy in diabetic ESRD patients?
The expected life span was calculated using state-specific
life tables [7]. A ratio of observed/expected survival was
METHODS
calculated for each patient [7]. The median or 0.5 ob-
The study cohort consisted of all type 1 diabetic pa- served/expected survival for a population, defined as the
tients who developed ESRD between the ages of 21 and percentage of patients who reached 0.5 observed/ex-
40 and received an initial kidney or SPK transplantation pected life span, was analyzed by Kaplan–Meier method-
at the University of Wisconsin between 1966 through De- ology.
cember 31, 1995. Data on each individual were obtained Data are reported as mean 6 SD. Differences in pro-
from a pretransplant clinical file, and prospectively com- portions and means were tested using the chi-square and
piled post-transplant and institution-specific dialysis da- t-test, respectively. A P value , 0.05 was considered
tabases. Study entry was defined as the date of admission significant. Statistical analyses of the data set were per-
to the center’s dialysis program or date of transplanta- formed using SAS statistical software (SAS Institute,
tion. Follow-up was terminated on December 31, 1998, Inc., Cary, NC, USA).
or at time of death or at last follow-up clinic visit.
The SPK and age-range–matched diabetic renal trans-
RESULTSplant recipient cohort was analyzed to evaluate the im-
pact of certain variables on patient and renal allograft Observed/expected life span was calculated for 335
SPK, 147 cadaveric (DM-Cad), and 160 living-donorsurvival. Recipient parameters examined that were han-
dled as categorical variables included race (Caucasian (DM-Live) transplant recipients. Demographic charac-
teristics for these individuals are shown in Table 1. Thevs. other races given the proportion of Caucasian patients
who receive transplants in our program), history of pre- average follow-up for these patients was 13 6 5.9 years.
There were no significant differences in age at the timetransplant dialysis (yes or no), and use of mycophenolate
mofetil (yes or no). Other variables that were examined of transplant or duration of diabetes prior to transplanta-
tion. The vast majority of patients, greater than 80%,included age at transplant, duration of diabetes prior to
transplant, pretransplant serum creatinine (SCr), SCr at were Caucasian, and male patients slightly outnumbered
female transplant recipients.discharge from transplant hospitalization, patient height,
weight, body mass index (BMI), human lymphocyte anti- There were 96 deaths in the DM-Cad cohort, 68 deaths
in the DM-Live patient groups, and 35 deaths in the SPKgen (HLA)-A, -B, and -DR matching. Donor variables
that were examined included cytomegalovirus (CMV) cohort during the study time period. The initial analysis
focused on the impact of SPK transplantation on patientstatus, race, age, and weight. A Cox proportional hazards
model was used to assess the main effects of potential survival. The absolute patient survival is shown in Figure
1. In addition to the diabetic patients, this analysis in-risk factors and their interactions with patient groups
on patient survival and renal graft loss. Rejection rates, cluded 492 age-range–matched 18 renal allograft recipi-
ents. These patients had higher rates of survival followingreadmission rates, CMV infection rates, and cardiac
death rates were estimated using Kaplan–Meier method- transplantation compared with patients in the other
transplant groups (18 renal vs. all others, P 5 0.0029).ology and were compared using the log-rank test.
An additional cohort of patients, age-range–matched SPK transplant recipients had a significantly greater per-
centage survival compared with age-range–matchedpatients who received either a cadaveric or living-donor
renal transplant for nondiabetic, nonhypertensive renal DM-Live and DM-Cad recipients (SPK vs. DM-Live and
DM-Cad, P 5 0.004).failure, were included in the observed/expected life span
analysis. These patients had chronic glomerulonephritis, Annual mortality rates for each patient cohort were
also calculated (Table 1). Not surprisingly, 18 renal pa-interstitial nephritis, congenital renal disease, polycystic
kidney disease, or genitourinary abnormalities as the tients had an AMR (1.7%) that was significantly less
than DM-Cad (6.27%) and DM-Live (18 renal vs. DM-cause of their renal failure and were designated as the
primary renal disease cohort (18 renal). Live and DM-Cad, 3.65%, P 5 0.008). However, the SPK
recipients’ AMRs (1.5%) were not significantly differentGraft survival time was calculated as the time interval
from transplantation to the date of graft failure or date from that of 18 renal patients.
To further evaluate the survival benefit of SPK trans-of last follow-up [8]. Patient survival was calculated as
the time from initial therapy for ESRD to death date plantation, we compared the ratio of observed/expected
life span among the selected patient groups. Seventy-sixor, if death was not reported, date of the last follow-up.
Survival curves were generated according to the Kaplan– percent of SPK patients reached their median or 0.5
observed/expected life span. This was not significantlyMeier method. The equality of the survivor function
across the different treatment or category groups was different from the percentage of 18 renal patients who
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Table 1. Patient demographics for transplant patients between ages 21 and 40
Characteristic 18 Renal DM-Cad DM-Live SPK
N 492 147 160 335
Gender M/F 290/202 81/66 97/63 204/131
% 59/41 55/45 60/40 61/39
Age years 30.266.8 32.366.4 31.366.3 3465.9
Race %
Caucasian 389a (79) 120a (82) 112a (70) 328a (98)
African American 74 (15) 7 (5) 2 (2) 3 (1)
Other 29 (6) 3 (2) 1 (1)
Not defined 17 (11) 45 (28) 3 (1)
Duration of diabetes years N.A. 17 67 1865.8 1668
Pretransplant dialysis (Yes/No) 352/140 (72/28) 108/39 (73/27) 110/50 (69/31) 206/129 (62/38)
Annual mortality rate (AMR) % 1.7% 6.27% 3.65% 1.5%b
aP # 0.001 vs. other races
bP 5 0.008 vs. DM-Cad, DM-Live; N.S. vs. 18 renal
mained even when analyzing SPK patients who had been
on dialysis prior to transplantation (Fig. 2B).
To avoid the potential bias introduced by the increas-
ing number of SPK transplants that occurred at our insti-
tution since the introduction of mycophenolate mofetil,
a separate analysis also was performed, analyzing SPK
(N 5 215) versus DM-Live (N 5 111) patient survival
and observed/expected life span for these patient groups
who received their transplants between 1985 and 1993.
SPK patients manifested a significantly greater survival
(P 5 0.03; Fig. 3). Furthermore, a greater percentage of
SPK recipients were estimated to reach their median
observed/expected life span (78%) than DM-Live pa-
tients (68%, P 5 0.001).
Since SPK median observed/expected life span ap-
proximated that of the 18 renal cohort, we were inter-Fig. 1. Kaplan-Meier estimates of simultaneous pancreas-kidney (SPK),
diabetic cadaveric (DM-Cad), live-donor (DM-Live), and the primary ested in determining variables that might have salutary
renal disease cohort (18 renal; defined in the Methods section) transplant
effects on SPK recipient survival in comparison to thepatient survival. *P 5 0.0029 18 renal vs. all others; **P 5 0.004 SPK
DM-Cad and DM-Live patients. A number of character-vs. DM-Cad, DM-Live.
istics were examined that might distinguish SPK recipi-
ents from DM-Cad and DM-Live patients in terms of
patient survival (Table 2). Race, duration of diabetes,
reached their median observed/expected life span (77%). pretransplant creatinine, BMI, HLA matching, donor
In an attempt to account for population variability, the age, weight, race, and CMV status had no significant
same analysis was undertaken by matching the popula- impact on the overall DM transplant patient mortality.
tions for race. In this analysis, 18 renal patients mani- Indeed, the only variable associated with an increased
fested a trend toward a higher percentage of patients overall mortality risk was a higher discharge SCr value
achieving their median or 0.5 observed/expected life span following the incident transplant hospitalization (RR
(81%, P 5 0.078). In contrast, only 70% of DM-Live 1.16 for each 0.1 mg/dL, P # 0.0154). When SPK patients
patients (P 5 0.002 vs. SPK) and 39% of DM-Cad pa- were compared with DM-Cad patients, a number of vari-
tients (P 5 0.003 vs. SPK) achieved their median or 0.5 ables lowered the relative mortality risk for SPK patients,
observed/expected life span. To gauge better the poten- including a shorter duration of diabetes (P 5 0.001), no
tial impact of transplant survival in the contemporary pretransplant dialysis (P 5 0.001), use of mycophenolate
era of immunosuppression, observed/expected life spans mofetil (P 5 0.001), and younger donor age (P 5 0.001).
for SPK and other DM transplant patients, transplanted However, these characteristics did not reduce mortality
after 1985 (Fig. 2A), were also evaluated. The median risk when comparing SPK with DM-Live transplant re-
observed/expected life span for SPK patients was sig- cipients (P 5 NS for each).
nificantly greater than age-range–matched diabetic Given the apparent importance of renal function at
discharge following the transplant hospitalization, fac-transplant recipients (P 5 0.0021). This advantage re-
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Fig. 2. (A) Observed/expected life span for SPK (N 5 335), diabetic cadaveric (DM-Cad, N 5 102), live-donor (DM-Live, N 5 126), *P 5 0.0021
SPK vs. DM-Cad and DM-Live. (B) Observed/expected life span for SPK patients who were on dialysis at the time of transplant (N 5 206)
compared with diabetic cadaveric (DM-Cad) (N 5 102) and live-donor (DM-Live, N 5 126) renal transplant recipients. *P 5 0.01 SPK vs. DM-
Cad and DM-Live.
for earlier renal graft loss in SPK recipients (RR 1.061
for each year of diabetes, P 5 0.01).
We also examined rates of hypertension, poor gly-
cemic control, and rejection episodes, as each could in-
fluence renal graft survival. Glycosylated hemoglobin
values . 6.5 mg/dL in SPK patients were associated with
an increased rate of renal graft failure (P 5 0.0002), as
was a mean systolic blood pressure greater than 140
mm Hg (P 5 0.0083). Interestingly, SPK recipients also
had significantly higher rates of renal allograft rejection
(P 5 0.0003) compared with DM-Cad and DM-Live
patients (Table 3).
Finally, any history of diabetes and renal failure can
predispose to multiple vascular and infectious complica-
tions. Kalker et al demonstrated that pancreas trans-
plantation did not significantly affect amputation ratesFig. 3. Kaplan–Meier estimates of SPK (N 5 215) vs. live-donor (DM-
Live, N 5 111) transplant recipient patient survival in patients trans- in diabetic transplant recipients in a retrospective study
planted between 1985 and 1993 (pre-mycophenolate mofetil, *P 5 0.03). that encompassed a large percentage of patients evalu-
ated in this analysis [9]. Therefore, we chose to focus on
other possible outcome measures: rates of hospitaliza-
tion, CMV infection, and cardiac death. SPK patientstors affecting renal graft survival were also evaluated.
incurred significantly higher rates hospital readmissionRenal graft survival in the SPK population was equiva-
in the first year following transplantation (P 5 0.0003)lent to that observed in DM-Live patients (Fig. 4). In
and a trend toward a greater number of CMV infections
both cases, renal graft survival was significantly greater (P 5 0.07; Table 3). Interestingly, there were no signifi-
compared with DM-Cad patients (P 5 0.002). A higher cant differences in cardiac death rates between patient
discharge SCr also was associated with a reduction in groups when assessed in their entirety. However, age
renal allograft survival in each cohort (RR 1.18 for each stratifying the patient cohorts unmasked significant dif-
0.1 mg/dL increase, P 5 0.0001). The only other charac- ferences in cardiac death rates in transplant patients be-
teristic that was significantly associated with a preferen- tween ages 30 and 39. SPK recipients (N 5 202) had
tial effect on SPK renal graft outcome was older donor significantly fewer cardiac deaths than DM-Live (N 5
age (RR 1.027 for each year, P 5 0.015). Interestingly, 59, P 5 0.005 vs. SPK) and DM-Cad (N 5 57, P 5 0.004
vs. SPK) patients in this age category.a longer duration of diabetes conferred an increased risk
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Table 2. Impact of variables on young diabetic kidney transplant recipient survival
Characteristic Patient survival (all) SPK vs. DM-Cad SPK vs. DM-Live
Race NS P50.0001, RR50.44
Duration of diabetes prior to transplant NS P50.0001, RR50.45 NS
Pre-Tx SCr NS P50.0001, RR50.41 NS
Discharge SCr P#0.0154; RR 1.16 P50.0001, RR50.41 NS, P50.052, RR50.632
Pre-Tx dialysis NS P50.0001, RR50.47 NS
BMI NS NS NS
HLA-A match NS P50.0001, RR50.44 NS
HLA-B match NS P50.0001, RR50.44 NS; P50.07, RR50.6
HLA-DR match NS P50.0001, RR50.42 NS; P50.057, RR50.61
MMF use NS P50.0001, RR50.45 NS
Donor age NS P50.0001, RR50.44 NS
Donor weight NS P50.0001, RR50.33 NS
Donor race NS P50.0001, RR50.44 NS
Donor CMV status NS P50.0004; RR50.41 NS
Abbreviations are: RR, relative risk; Tx, transplant; SCr, serum creatinine; BMI, body mass index; MMF, mycophenolate mofetil; CMV, cytomegalovirus. The
number of patients was: N 5 335 for SPK, N 5 160 for DM-Live, N 5 147 for DM-Cad. The RR for pre-Tx SCr was handled as a continuous variable and the RR
for discharge SCr was calculated for every 0.1 mg/dL . 1.0 mg/dL.
SPK patients achieved observed/expected life spans that
were not significantly different from 18 renal patients.
Why did SPK patients fare so well? Pre-emptive trans-
plantation is one possibility. Residual renal function may
significantly potentiate survival following transplanta-
tion [8, 12]. Indeed, more than 35% of the SPK recipients
in this study were not yet on dialysis, compared with less
than 25% of the DM-Cad and DM-Live recipients.
The fact that SPK patients experienced complications
at rates greater than DM-Cad and DM-Live patients is
not surprising. Other studies have demonstrated similar
findings [13, 14]. However, it is possible that the care
associated with such complications enhanced an encoun-
ter bias whereby SPK patients were followed up more
often and had earlier and more frequent medical inter-
ventions compared with DM-Cad and DM-Live patients.
Fig. 4. Kaplan-Meier estimates of SPK (N 5 335), diabetic cadaveric Interestingly, SPK recipients had rates of cardiac death
(DM-Cad, N 5 147), and live-donor (DM-Live, N 5 160) renal graft that were equivalent to or better than DM-Cad or DM-survival. *P 5 0.002 SPK vs. DM-Cad and DM-Live vs. DM-Cad; P 5
Live recipients. Low cardiac risk patients are acceptedNS SPK vs. DM-Live.
for SPK transplantation at our center [8]. This may ac-
count for some of the disparity between our results and
those reported by Manske, Wang, and Thomas [6], who
DISCUSSION noted that a history of congestive heart failure signifi-
Restoring life span and quality of life are two of the cantly increased mortality risk for SPK patients. How-
most important goals of medical therapy. For patients ever, Gaber et al have suggested that SPK transplanta-
with a chronic illness, years gained as the result of an tion may actually improve short-term cardiovascular risk
intervention can be assessed in many ways [10]. We chose [15]. Their echocardiographic study demonstrated im-
to analyze that incremental increase in life span by com- provements in left ventricular hypertrophy in SPK pa-
paring it to an individual’s “normal” life span in that tients compared with other diabetic transplant recipients.
population [7]. In so doing, this single-center retrospec- One mechanism for the improvements in cardiovascu-
tive study highlighted the differences in life expectancy lar risk associated with SPK transplantation could be the
achieved by SPK transplantation in comparison to kid- restoration of normoglycemia. Several large epidemio-
ney transplantation alone in type 1 diabetic patients with logic studies have demonstrated that hyperglycemia is a
ESRD. risk factor for progression of atherosclerosis and coro-
Simultaneous pancreas-kidney recipient survival was nary heart disease [16–20]. It is possible that restoration
greater than that of DM-Cad and DM-Live patients, simi- of normoglycemia affects the myocardial vascular bed
differently, especially with the aforementioned salutarylar to the report of Douzdjian et al [11]. More importantly,
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Table 3. Patients free of complication at one year
Complication DM-Cad DM-Live SPK P value
Renal graft rejection 57.2% 57.1% 34.6% P50.0003
SPK vs. DM-Cad, DM-Live
CMV infection 93% 92% 86% P50.07
SPK vs. DM-Cad, DM-Live
Readmission 49% 51% 22% P50.0003
SPK vs. DM-Cad, DM-Live
effects in reducing left ventricular mass, such that SPK Live and SPK recipients between 1985 and 1993. These
time points were chosen as cyclosporine A became stan-recipients have improvements in long-term cardiac sur-
vival. Long-term analyses in the diabetic transplant pop- dard immunosuppressive therapy at our center after
1985, and there were no other marked changes in immu-ulation are necessary to answer this question definitively.
Restoring normoglycemia may have even more pro- nosuppression until 1993, with the use of mycophenolate
mofetil. Limiting the analysis to age-range–matched indi-found effects on SPK patient survival aside from these
theoretical benefits. The Diabetes Complications and viduals further reduced the likelihood for mismatched
demographics influencing the results, especially in thatControl Trial demonstrated that intensive insulin ther-
apy slowed the progression of retinopathy and neuropa- era when the “experimental” nature of SPK transplanta-
tion steered many individuals to choose DM-Live ratherthy and reduced the occurrence of microalbuminuria in
type 1 diabetic patients [21]. SPK, by restoring normogly- than SPK transplantation. However, SPK recipients
from that era still demonstrated significant improve-cemia, appears to have the same effects [22] to prevent
or stabilize diabetic complications including retinopathy ments in absolute survival and median observed/ex-
pected life span compared with DM-Live patients.[2], neuropathy [3], and the development of recurrent
In summary, this study highlights important considera-diabetic nephropathy in simultaneously transplanted
tions in evaluating life span for type 1 diabetic patientskidneys [23]. Tyden et al recently suggested that restor-
with ESRD. Renal transplant outcomes traditionallying normoglycemia with SPK transplantation, even after
have been measured in short-term patient and graft sur-a long history of diabetes, may be the most significant
vival. Improvements in immunosuppression and post-factor positively affecting survival in SPK recipients [22].
transplant care, however, have challenged the adequacyIn our population, long-term pancreas graft function
of these measures. We are now beginning to focus onnearly mirrors survival [24] and supports the premise
long-term survival. SPK transplantation appears to con-that restoration of normoglycemia has marked effects on
fer better long-term survival for type 1 diabetic patientspatient survival, even as a late intervention in a diabetic
with ESRD than any previously defined therapy [22, 25].patient’s lifetime.
By applying a different measure of survival (observed/Certain caveats should be considered when interpre-
expected life span), we clearly demonstrated the benefi-ting this study. This is a single-center, retrospective study
cial effect of SPK transplantation on survival in our pop-with all of the inherent limitations of such analyses. Many
ulation, the largest reported to date. SPK transplantationpatients included in this analysis were referred to our
increased the ratio of observed/expected life span achievedcenter for transplantation, having received their pre-
by SPK recipients such that their survival was nearlyESRD care and, in some cases, dialytic care elsewhere,
indistinguishable from that of age-range–matched trans-complicating assessment of their pretransplant charac-
plant recipients with nondiabetic renal disease.teristics. Finally, while our center’s standard criteria for
patient selection have been published [24], this analysis
ACKNOWLEDGMENTScannot account for selection bias, especially the potential
for cardiac-related preselection bias in choosing lower This work was supported in part by National Institutes of Health
grant DK-02420 (B.N.B.). The authors acknowledge the outstandingrisk patients for the SPK transplant procedure [24]. The
efforts of the data coordinators, nurses, and support staff who caremost stringent comparison population for SPK recipients for all of the University of Wisconsin transplant patients.
may be age-matched DM-Live patients. However, pa-
Reprint requests to Bryan N. Becker, M.D., Division of Nephrology,tients in the post-1993 era of transplantation would rep-
University of Wisconsin Hospital and Clinics, H4/510 Clinical Scienceresent this bias, as SPK has been increasingly offered to Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA.
all eligible patients at our institution such that is the E-mail: bnb@medicine.wisc.edu
predominant transplant for type 1 diabetic patients. Rec-
ognizing that treatment modalities, in addition to selec- REFERENCES
tion criteria, have changed significantly during the time 1. U.S. Scientific Registry for Transplant Recipients and the
Organ Procurement and Transplantation Network: 1997 An-period covered by this study, we chose to focus on DM-
Becker et al: Life span and SPK transplantation 2135
nual Report—Transplant Data: 1988–1996, UNOS. Division of versus kidney alone transplantation. Transplantation 64:1288–1294,
1997Transplantation, Office of Special Programs, Health Resources and
14. Anonymous: Simultaneous kidney-pancreas transplantation ver-Services Administration, U.S. Department of Health and Human
sus kidney transplantation alone: patient survival, kidney graftServices, Rockville, MD, 1997
survival, and post-transplant hospitalization. Am J Kidney Dis2. Cheung ATW, Chen PCY, Leschinsky TV, Wiltse SL, Basa-
20:61–67, 1992donna GP, Katznelson S, Perez RV: Improvement in conjuncti-
15. Gaber AO, El-Gebely S, Sugathan P, Elmer DS, Hathawayval microangiopathy after simultaneous kidney-pancreas trans-
DK, McCully RB, Shokouh-Amiri MH, Burlew BS: Early im-plants. Transplant Proc 29:660–661, 1997
provement in cardiac function occurs for pancreas-kidney but not3. Nankivell BJ, Al-Harbi IS, Morris J, Clouston PD, O’Connell
diabetic kidney-alone transplant recipients. Transplantation 59:PJ, Chapman JR, Allen RDM: Recovery of diabetic neuropathy
1105–1112, 1995after pancreas transplantation. Transplant Proc 29:658–659, 1997
16. Balkau B, Shipley M, Jarrett RJ, Pyorola K, Pyorola M, For-4. Rosen CB, Frohnert PP, Velosa JA, Engen DE, Sterioff S:
han A, Eschwege E: High blood glucose concentration is a riskMorbidity of pancreas transplantation during cadaveric renal trans-
factor for mortality in non-diabetic men: 20-Year follow-up inplantation. Transplantation 51:123–127, 1991
the Whitehall Study, Paris Prospective Study, and the Helsinki5. Corry RJ, Ngheim DD, Schulak JA, Beutel WD, Gonwa TA:
Policemen Study. Diabetes Care 21:360–367, 1998Surgical treatment of diabetic nephropathy with simultaneous pan- 17. Donahue RP, Abbott RD, Reed DM, Yano K: Postchallenge
creatic duodenal and renal transplantation. Surg Gynecol Obstet glucose concentration and coronary heart disease in men of Japa-
162:547–555, 1986 nese ancestry: Honolulu Heart Program. Diabetes 36:689–692, 1987
6. Manske CL, Wang Y, Thomas W: Mortality of cadaveric kidney 18. Haffner SM: Epidemiological studies on the effects of hyperglyce-
transplantation versus combined kidney-pancreas transplantation mia and improvement of glycemic control on macrovascular events
in diabetic patients. Lancet 346:1658–1662, 1995 in type 2 diabetes. Diabetes Care 22(Suppl 3):C54–C56, 1999
7. Becker BN, Becker YT, Pintar TJ, Collins BH, Pirsch JD, 19. Cooper R, Liu K, Stamler J, Schoenberger JA, Shekelle RB,
Friedman A, Sollinger HW, Brazy PC: Using renal transplanta- Collette P, Shekelle S: Prevalence of diabetes/hyperglycemia
tion to evaluate a simple approach for predicting the impact of and associated cardiovascular risk factors in blacks and whites:
end-stage renal disease therapies on patient survival: Observed/ Chicago Heart Association Detection Project in Industry. Am
expected life span. Am J Kidney Dis (in press) Heart J 108:827–833, 1984
20. Ostrander LD Jr, Lamphiear DE, Carman WJ, Williams GW:8. Lin H-M, Kauffman M, McBride MA, Davies DB, Rosendale
Blood glucose and risk of coronary heart disease. ArteriosclerosisJD, Smith CM, Edwards EB, Daily OP, Kirklin J, Shield CF,
1:33–37, 1981Hunsicker LG: Center-specific graft and patient survival rates
21. Diabetes Control and Complications Trial (DCCT) Research1997 United Network for Organ Sharing (UNOS) Report. JAMA
Group: The effect of intensive treatment of diabetes on the devel-280:1153–1160, 1998
opment and progression of long-term complications in insulin-9. Kalker AJ, Pirsch JD, Heisey D, Sollinger HW, Belzer FO,
dependent diabetes mellitus. N Engl J Med 329:976–986, 1993Knechtle SJ, D’Alessandro AM: Foot problems in the diabetic
22. Tyden G, Bolinder J, Solders G, Brattstrom C, Tibell A, Grothtransplant recipient. Clin Transplant 10:503–510, 1996
C-G: Improved survival in patients with insulin-dependent diabetes10. Wright JC, Weinstein MC: Gains in life expectancy from medical
mellitus and end-stage diabetic nephropathy 10 years after com-interventions: Standardizing data on outcomes. N Engl J Med
bined pancreas and kidney transplantation. Transplantation 67:339:380–386, 1999
645–648, 199911. Douzdjian V, Rice JC, Gugliuzza KK, Fish JC, Carson RW: 23. Bohman SO, Tyden G, Wilczek H, Lundgren G, Jaremko G,
Renal allograft and patient outcome after transplantation: Pan- Gunnarsson R, Ostman J, Groth CG: Prevention of kidney graft
creas-kidney versus kidney-alone transplants in type 1 diabetic diabetic nephropathy by pancreas transplantation in man. Diabetes
patients versus kidney-alone transplants in nondiabetic patients. 34:306–308, 1985
Am J Kidney Dis 27:106–116, 1996 24. Sollinger HW, Odorico JS, Knechtle SJ, D’Alessandro AM,
12. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ: Impact Kalayoglu M, Pirsch JD: Experience with 500 simultaneous pan-
of renal cadaveric transplantation on survival in end-stage renal creas-kidney transplants. Ann Surg 228:284–296, 1998
failure: Evidence for reduced mortality risk compared with hemo- 25. Smets YFC, Westendorp RGJ, Van Der Pijl JW, De Charro FT,
dialysis during long-term follow-up. J Am Soc Nephrol 9:2135– Ringers J, De Fijter JW, Lemkes HHPJ: Effect of simultaneous
2141, 1998 pancreas-kidney transplantation on mortality of patients with
13. Lee CM, Scandling JD, Krieger NR, Dafoe DC, Alfrey EJ: type-1 diabetes mellitus and end-stage renal failure. Lancet 353:
1915–1919, 1999Outcomes in diabetic patients after simultaneous pancreas-kidney
